Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome
Prue M Pereira-Fantini, Susan Lapthorne, Cormac GM Gahan, Susan A Joyce, Jenny Charles, Peter J Fuller, Julie E Bines
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY | ELSEVIER INC | Published : 2017
BACKGROUND & AIMS: Options for the prevention of short-bowel syndrome-associated liver disease (SBS-ALDs) are limited and often ineffective. The farnesoid X receptor (FXR) is a newly emerging pharmaceutical target and FXR agonists have been shown to ameliorate cholestasis and metabolic disorders. The aim of this study was to assess the efficacy of obeticholic acid (OCA) treatment in preventing SBS-ALDs. METHODS: Piglets underwent 75% small-bowel resection (SBS) or sham surgery (sham) and were assigned to either a daily dose of OCA (2.4 mg/kg/day) or were untreated. Clinical measures included weight gain and stool studies. Histologic features were assessed. Ultraperformance liquid chromatogra..View full abstract
Awarded by National Health and Medical Research Council of Australia
Awarded by Science Foundation Ireland
This work was supported by the National Health and Medical Research Council of Australia through a Senior Principal Research Fellowship (1002559 to P.J.F.); and Murdoch Childrens Research Institute and Hudson Medical Research Institute are supported by the Victorian Government's Operational Infrastructure Program. This publication has emanated from research supported in part by a research grant SFI/12/RC/2273 from the Science Foundation Ireland.